Recent Advances in the Development of TGF-β Signaling Inhibitors for Anticancer Therapy
Journal of Cancer Prevention
; : 213-222, 2020.
Article
en En
| WPRIM
| ID: wpr-891328
Biblioteca responsable:
WPRO
ABSTRACT
TGF-β is a multifunctional cytokine that plays an important role in both physiologic and pathologic processes, including cancer. Importantly, TGF-β has a dual role in tumorigenesis, acting as a tumor suppressor or a tumor promoter, depending on the stage of tumor development. The aberrantly upregulated production of TGF-β has been strongly implicated in tumor progression, angiogenesis, and metastasis, as well as immune evasion. Therefore, hyperactivated TGF-β signaling is considered a potential therapeutic target for cancer therapy. Numerous inhibitors of overactivated TGF-β signaling have been developed, and some of them are currently in clinical trials. This review focuses on the TGF-β signaling that contributes to tumor progression and immune evasion in the tumor microenvironment and presents recent achievements on TGF-β signaling inhibition as a single or combined therapeutic approach in cancer therapy.
Texto completo:
1
Índice:
WPRIM
Idioma:
En
Revista:
Journal of Cancer Prevention
Año:
2020
Tipo del documento:
Article